
|Videos|December 28, 2018
Prevalence of RET Mutations in Lung and Thyroid Cancers
Author(s)Alexander E. Drilon, MD
Alexander E. Drilon, MD, discusses the prevalence of <em>RET</em> fusions and mutations in patients with cancer, including lung and thyroid cancers.
Advertisement
Alexander E. Drilon, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the prevalence ofRETfusions and mutations in patients with cancer, including lung and thyroid cancers.
In lung cancer, or more specifically nonsmall cell lung cancer, where there are about 200,000 cases every year,RETmutations affect up to 2% of the population. In papillary thyroid cancer,RETmutations are found in 10% to 20% of patients.
In medullary thyroid cancer,RET
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5

































